Gland Pharma Limited Earnings Summary — Q1 FY2027
Gland Pharma Reports Strong YoY Growth in Q1 FY27 Amid Margin Compression and Revenue Scale-up
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 4 consecutive quarters.
- Revenue of ₹1,800 Cr is 19.6% higher year-on-year.
- Revenue has compounded at 7.3% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹317 Cr is 47.1% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 24.8% annualised across the period.
- Operating margin stands at 27.2% in Q1 FY2027.
- Operating margin expanded by 275 bps year-on-year.
- Over the last two years operating margin has expanded by 832 bps.
- PBT margin is 24.2%.
- Expense growth of 15.2% remained below revenue growth of 19.6%.
- Operating profit of ₹489 Cr is 33.1% higher year-on-year.
- Operating leverage continues to improve.
- 5 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 76/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Stable | 1,800 | 1,743 | 1,695 | 1,487 | 1,506 | 1,425 | 1,384 | 1,406 | 1,402 | 1,537 |
| Expenses | Stable | 1,311 | 1,230 | 1,260 | 1,173 | 1,138 | 1,077 | 1,024 | 1,109 | 1,137 | 1,179 |
| Operating Profit | Accelerating | 489 | 513 | 435 | 314 | 368 | 348 | 360 | 297 | 264 | 359 |
| Operating Margin | Stable | 27.2% | 29.4% | 25.6% | 21.1% | 24.4% | 24.4% | 26.0% | 21.1% | 18.9% | 23.3% |
| Other Income | Volatile | 61 | 111 | 39 | 84 | 58 | 44 | 58 | 60 | 51 | 42 |
| Interest | Volatile | 4 | 10 | 4 | 8 | 12 | 7 | 23 | 6 | 6 | 10 |
| Depreciation | Stable | 111 | 109 | 108 | 106 | 101 | 96 | 96 | 94 | 92 | 93 |
| Profit Before Tax | Accelerating | 435 | 506 | 362 | 284 | 313 | 288 | 299 | 257 | 218 | 298 |
| Tax | Stable | 118 | 139 | 101 | 100 | 97 | 102 | 95 | 93 | 74 | 106 |
| Net Profit | Accelerating | 317 | 367 | 261 | 184 | 215 | 187 | 205 | 164 | 144 | 192 |
| Net Margin | Accelerating | 17.6% | 21.0% | 15.4% | 12.3% | 14.3% | 13.1% | 14.8% | 11.6% | 10.3% | 12.5% |
Key Takeaways
- Revenue for Q1 FY27 reached ₹18,002.71 million, representing a robust 19.6% year-on-year growth compared to Q1 FY26.
- Net Profit attributable to owners grew 47.1% YoY to ₹3,169.59 million, though it saw a sequential decline of 13.6% from the previous quarter.
- Operating margins have shown signs of stabilization compared to last year but remain pressured sequentially due to shifts in product mix and increased employee benefit expenses.
- The Cenexi acquisition integration continues to impact the consolidated balance sheet, evidenced by higher depreciation and finance costs compared to historical standalone levels.
- The company maintains a strong balance sheet with substantial total equity of ₹103,579.70 million as of the end of the previous fiscal year.
- Total expenses rose to ₹14,265.23 million, driven largely by cost of materials consumed and employee benefits as the company scales its operations.
Management Guidance
Management is focused on leveraging its manufacturing moat in sterile injectables and expanding its CDMO services. While facing pricing pressures in the US generic market, the strategy involves a shift toward complex molecules to protect long-term margins.
Sentiment Shift
Improving
Year-on-year performance shows significant recovery in both revenue and profit, although sequential margin compression suggests ongoing pricing challenges in core markets.
Outlook
Gland Pharma expects to continue its growth trajectory by expanding its global footprint and integrating Cenexi's capabilities. The focus remains on navigating US FDA inspections and managing supply chain complexities inherent in sterile manufacturing.
From the Annual Report (Key Quotes)
“The Statement of Unaudited Consolidated Financial Results... has been reviewed by the Audit Committee and approved by the Board of Directors.”
“The Group is engaged in the manufacture and sale of 'Pharmaceuticals' which constitutes a single reportable business segment.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Gland Pharma Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.